Clinical trials: Immune Deficiency Disorders
Hiv
Exploring a Digital HIV Onward Disclosure Intervention, in People Living With HIV of Sub-Saharan African Ethnicity.
Research has shown that people living with HIV struggle to disclose their HIV status to others, (a process known as self-disclosure or onward disclosure) due to associated challenges, including fear of discrimination from others.
- Trial name
- NCT05804968
- Testing
- Digital HIV Self Disclosure Intervention
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Royal Holloway University
In Utero Drug Exposure
Cardiometabolic Health of Children Exposed to Anti-retroviral Therapy (ART) in Utero
The Human Immunodeficiency Virus (HIV) has been recently linked to increased risk for cardiovascular diseases (CVDs). The prevalence of cardiovascular diseases and its risk factor, hypertension, are very high in African…
- Trial name
- ARTMOMSBABES (NCT04763668)
- Testing
- Pregnant HIV positive women on ARTs, Babies born to HIV positive mothers on ARTs
- Where
- South Africa
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- Walter Sisulu University
HIV Disease
Therapy to Elevate CD4 Counts in HIV-1 Disease
For more than 20 years, alpha-1-proteinase inhibitor therapy has been the standard treatment for patients who have inherited alpha-1-proteinase inhibitor deficiency.
- Trial name
- NCT01370018
- Testing
- alpha-1-Proteinase Inhibitor
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Institute for Human Genetics and Biochemistry
HIV Infections
Safety of and Immune Response to the Experimental Preventive HIV Vaccine, EP HIV-1090, in Healthy, HIV-1 Uninfected Adults
The purpose of the study is to determine the safety of and immune response to the investigational HIV vaccine, EP HIV-1090, in HIV uninfected adults.
- Trial name
- NCT00141024
- Testing
- EP HIV-1043, EP HIV-1090
- Where
- 3 sites in United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Sexually Transmitted Disease
Effect of HIV/STD Risk Reduction Program on South African Adolescents
This study will evaluate the effect of an HIV/STD risk-reduction program on the sexual behavior of South African adolescents.
- Trial name
- NCT00559403
- Testing
- HIV/STD Risk-Reduction, Health Promotion
- Volunteers
- 1,057 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
HIV/AIDS
Type 1 Hybrid Trial of Our Plan - a Brief, Couples-based HIV/STI Prevention Intervention
This webapp, couples-based HIV/STI prevention intervention project will use a Type 1 Hybrid Design Trial to determine efficacy to reduce HIV risk via uptake of evidence-based strategies and a tailored prevention plan among male…
- Trial name
- NCT05193942
- Testing
- Intervention Our Plan, Internation Informational Control
- Where
- United States
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- Florida International University
Medication Adherence, HIV/AIDS
A Mobile Gaming App to Improve Adherence to PrEP
In this study, the investigators will test the mobile game, Viral Combat, for efficacy and acceptability among diverse participants, ages 15-34 years, receiving PrEP care in clinical settings in New England and Mississippi.
- Trial name
- NCT05762705
- Testing
- Multilevel Gaming Adherence Intervention, Treatment as Usual +
- Where
- 3 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Rhode Island Hospital
Mevalonate Kinase Deficiency
Geranylgeraniol Supplementation in Patients With Mevalonate Kinase Deficiency
Mevalonate kinase deficiency (HyperIgD syndrome, HIDS) is an inborn error of immunity caused by a block in the mevalonate pathway.
- Trial name
- NCT06497829
- Testing
- geranylgeraniol
- Where
- Czechia
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- University Hospital, Motol
Osteoporosis, Fractures
Determination of Optimum Age for DXA Screening for Osteoporosis in HIV - The Probono 1 Study
The purpose of this study is to determine the bone mineral density in male and female patients with HIV infection according to age groups.
- Conditions
- Osteoporosis, Fractures, HIV Infection
- Trial name
- Probono1 (NCT01669954)
- Where
- United Kingdom
- Volunteers
- 440 people, healthy volunteers welcome
- Sponsor
- King's College London
Pancreatic Ductal Adenocarcinoma, Pancreatic Cyst
The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
The long-term goal of our PIC is to develop effective strategies that can be applied clinically at the point-of-care to prevent, intercept, or detect PDAC at an early stage, thereby reducing PDAC burden and saving lives.
- Conditions
- Pancreatic Ductal Adenocarcinoma, Pancreatic Cyst, Chronic Pancreatitis, Fatty Pancreas
- Trial name
- NCT05692596
- Testing
- Data collection
- Where
- United States
- Volunteers
- 317 people, healthy volunteers welcome
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Cryptococcal Meningitis
Vietnam Cryptococcal Retention in Care Study (CRICS) Federal Financial Report
CRICS financial report for the first budget year of the study
- Trial name
- NCT02955862
- Testing
- Vietnam Cryptococcal Retention in Care Study (CRICS)
- Where
- Vietnam
- Volunteers
- 1,177 people, healthy volunteers welcome
- Sponsor
- National Hospital for Tropical Diseases, Hanoi, Vietnam
HIV Infections, Acquired Immune Deficiency Syndrome
Reactogenicity and Immunogenicity of Vaginal CNgp140
To determine the local (cervico-vaginal) and systemic (whole body) safety of vaginal immunisation with CN54gp140 glycoprotein administered 9 times over a 3 week period.
- Trial name
- SG06RS02 (NCT00637962)
- Testing
- HIV glycoprotein CN54gp140 (vaccine), Carbopol 974
- Where
- 2 sites in United Kingdom
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- St George's, University of London
HIV Infections
A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV Envelope Protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in Healthy, HIV-1 Uninfected Adults
This a phase 1 first-in-human clinical trial to evaluate the safety, tolerability, and immunogenicity of BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in up to 60 healthy adult HIV-uninfected volunteers.
- Trial name
- NCT03699241
- Testing
- BG505 SOSIP.664 gp140, adjuvanted
- Where
- 3 sites in United States, Kenya
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- International AIDS Vaccine Initiative
Human Immunodeficiency Virus (HIV)
Effect of Seminal Fluid on the Colon Wall; Implications for HIV Transmission
This research is being done to learn how seminal fluid affects the lining of the colon, and whether this might make it easier for HIV to get into the body and cause infection.
- Trial name
- NCT01053741
- Testing
- Radiolabeled autologous seminal fluid, Radiolabeled Normosol-R
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
HIV Infections
Observational Study of Blood Treated With Cytolin
Primary Objective: To determine the mechanism of Cytolin's effect on HIV replication from blood drawn from HIV-positive and HIV-negative individuals after exposure to Cytolin.
- Trial name
- NCT01048372
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- CytoDyn, Inc.
HIV Infections
PrEP Seguro: Antiretroviral-based HIV Prevention Among Men at High Risk in Mexico
The objective of this R34 application is to prepare for testing innovative user-centered ways to promote PrEP adherence at scale.
- Trial name
- NCT03674983
- Testing
- Conditional Economic Incentive (CEI)
- Where
- Mexico
- Volunteers
- 310 people, healthy volunteers welcome
- Sponsor
- Brown University
HIV/AIDS
Study in Healthy Males to Measure Maraviroc in Blood, Saliva, Seminal Fluid, and Rectal Tissue
This study is being conducted to look at how the body handles the drug maraviroc. It will measure the amount of maraviroc in blood, semen, saliva and in the rectum of men.
- Trial name
- NCT00775294
- Testing
- Maraviroc
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
HIV Infections
Drug-drug Interaction (DDI) Study of GSK3640254 With Darunavir/Ritonavir (DRV/RTV) and Etravirine (ETR)
This is an open-label, single-sequence, multiple-dose, 3 cohort study to investigate the effects of DRV/RTV and/or ETR on the pharmacokinetics (PK) of GSK3640254 and the effects of GSK3640254 on the PK of DRV/RTV and/or ETR.
- Trial name
- NCT04630002
- Testing
- GSK3640254, Darunavir/Ritonavir (DRV/RTV), Etravirine (ETR)
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infections
Performance and Usability Evaluation of the Atomo HIV Self-Test
The study seeks to enroll 501+ patients to use a HIV self testing device to test for HIV in a blood sample drawn by finger prick.
- Trial name
- NCT03755986
- Testing
- ATOMO Diagnostic Test
- Where
- Australia
- Volunteers
- 520 people, healthy volunteers welcome
- Sponsor
- Holdsworth House Medical Practice
HIV/AIDS
Community-based, Peer-delivered PrEP for Female Sex Workers in Rural Uganda: The Peers for PrEP (P4P) Study
The overall goal of the P4P: Peers for PrEP (pre-exposure prophylaxis) study is to pilot test a peer-led and delivered intervention for biomedical HIV prevention that is tailored to women who engage in sex work in southwestern…
- Trial name
- P4P (NCT06353295)
- Testing
- P4P intervention
- Where
- Uganda
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco